Tuesday, 02 January 2024 12:17 GMT
عربي


               US          Europe          Arab          Asia          Africa    
|      Politics          Economy     Oil&Energy         
                 Entertainment          Sport
Biovaxys Technology Corp

Biovaxys Technology Corp


2026-05-01 03:10:10
(MENAFN- Baystreet) 10:39 AM EST - BioVaxys Technology Corp: Presents further validation of the Robust Immune Response from a combination of MVP-S with checkpoint inhibitors and low-dose cyclophosphamide in ovarian cancer. BioVaxys Technology Corp shares C are trading unchanged at $0.06.

Full Press Release:

MENAFN01052026000212011056ID1111060104



Baystreet.ca

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Tags

Label

Comments

No comment

Category

Date
Search